Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics

Butala, Ankur; Shepard, Melissa; Pontone, Gregory M.

doi:10.1016/b978-0-444-64012-3.00007-1

Cited by 13 publications

(11 citation statements)

References 538 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The slightly lower rates of lifetime anxiety disorders we observed may be due to the fact that MINI-Plus does not investigate anxiety disorders not otherwise specified, which have been found to be highly prevalent in PD [ 13 , 20 ]. Overall, studies conducted to evaluate the prevalence of anxiety disorders in PD have shown a wide variability with rates ranging between 25% and 60% [ 35 ], probably as a result of the scarce homogeneity in settings, tools and sample selection (i.e., age, severity of PD, psychiatric evaluation).…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease

Elefante

Brancati

Bacciardi

et al. 2021

JCM

View full text Add to dashboard Cite

Mood and anxiety disorders are the most common neuropsychiatric syndromes associated with Parkinson’s disease (PD). The aim of our study was to estimate the prevalence of lifetime and current anxiety disorders in patients with Parkinson’s Disease (PD), to explore possible distinctive neurological and psychiatric features associated with such comorbidity. One hundred patients were consecutively recruited at the Movement Disorders Section of the Neurological Outpatient Clinic of the University of Pisa. According to the MINI-Plus 5.0.0, 41 subjects were diagnosed with lifetime anxiety disorder (22 with panic disorder) and 26 were diagnosed with current anxiety disorders. Patients with anxiety disorders were more frequently characterized by psychiatric symptoms preceding PD, lifetime major depression and antidepressant treatments. They showed more anxious temperamental traits and scored higher at Parkinson Anxiety Scale (PAS) and persistent anxiety subscale. Current anxiety disorders were associated with more severe psychopathology, depressive symptomatology, and avoidant behavior. Among anxiety subtypes, patients with lifetime panic disorder showed higher rates of psychiatric symptoms before PD, lifetime unipolar depression, current psychiatric treatment, and a more severe psychopathology. Given the overall high impact of anxiety on patients’ quality of life, clinicians should not underestimate the extent of different anxiety dimensions in PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease

Elefante

Brancati

Bacciardi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Depression and anxiety are common features of PD that are both responses to the illness and integral components of the disease process [3,11,[44][45][46]. It is difficult to extricate those components that reflect daily events, such as frustration with completing activities of daily living and the cycles of symptomatic drug effect and the approach of 'OFF' periods, and events that reflect the widespread pathology of PD altering those parts of the circuitry that control mood and psychological state in general [47]. However, both are viewed as key components of the non-motor symptoms of PD.…”

Section: A Role For Adenosine a 2a Receptor Antagonists In The Treatmmentioning

confidence: 99%

“…It is probably fair to say that the precise mechanism by which A 2A receptor antagonism elicits antidepressant activity is not currently known. It may occur through the actions of A 2A antagonists on A 2A receptors modulating striatal output and influencing the basal gangliacortical loop system that controls affective behavior [47,61]. This would certainly seem likely in PD, but whether this would apply to major depression in otherwise normal individuals is not known and requires further study.…”

Section: Tablementioning

confidence: 99%

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Jenner

Mori

Kanda

2020

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…The positive symptoms of SCZ overlap with different psychiatric disorders. Indeed, psychosis is also frequent during mood episodes in BD, severe depression, substance use disorder and neurodegenerative disorders (16)(17)(18). Intriguingly, some SCZ-like psychopathological abnormalities (i.e., paranoid delusional thinking and auditory hallucinations) are expressed in an attenuated form in 5-8% of the otherwise healthy population, especially in individuals with schizotypal or schizoid personality traits (13,19).…”

Section: Introductionmentioning

confidence: 99%

Maternal Immune Activation and the Development of Dopaminergic Neurotransmission of the Offspring: Relevance for Schizophrenia and Other Psychoses

2020

View full text Add to dashboard Cite

Prenatal infections have been linked to the development of schizophrenia (SCZ) and other neurodevelopmental disorders in the offspring, and work in animal models indicates that this is to occur through the maternal inflammatory response triggered by infection. Several studies in animal models demonstrated that acute inflammatory episodes are sufficient to trigger brain alterations in the adult offspring, especially in the mesolimbic dopamine (DA) system, involved in the pathophysiology of SCZ and other disorders involving psychosis. In the current review, we synthesize the literature on the clinical studies implicating prenatal infectious events in the development of SCZ. Then, we summarize evidence from animal models of maternal immune activation (MIA) and the behavioral and molecular alterations relevant for the function of the DAergic system. Furthermore, we discuss the evidence supporting the involvement of maternal cytokines, such as interleukin 6 (IL-6) and leptin (a hormone with effects on inflammation) in mediating the effects of MIA on the fetal brain, leading to the long-lasting effects on the offspring. In particular, IL-6 has been involved in mediating the effects of MIA animal models in the offspring through actions on the placenta, induction of IL-17a, or triggering the decrease in non-heme iron (hypoferremia). Maternal infection is very likely interacting with additional genetic and environmental risk factors in the development of SCZ; systematically investigating how these interactions produce specific phenotypes is the next step in understanding the etiology of complex psychiatric disorders.

show abstract

Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics

Cited by 13 publications

References 538 publications

Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease

Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson’s Disease

Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Maternal Immune Activation and the Development of Dopaminergic Neurotransmission of the Offspring: Relevance for Schizophrenia and Other Psychoses

Contact Info

Product

Resources

About